Citadel Advisors’s Aktis Oncology AKTS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.26M Buy
115,857
+90,320
+354% +$2.2M ﹤0.01% 6450
2026
Q2
$823K Sell
25,537
-49,463
-66% -$1.02M ﹤0.01% 8685
2026
Q1
$1.34M Buy
+75,000
New +$1.46M ﹤0.01% 6980

Other funds holding AKTS

Citadel Advisors's AKTS Position: Q3 2026 in Review

Citadel Advisors increased its Aktis Oncology (AKTS) stake by 354% in Q3 2026, buying an estimated $2.2M and bringing the position to 115,857 shares worth $2.26M. The position accounts for ﹤0.01% of the portfolio, ranked #6450.

Citadel Advisors first reported a position in AKTS in Q1 2026 and has held it in 3 quarters since. 124 funds tracked by Wall St. Rank hold AKTS as of Q3 2026.

  • Citadel Advisors held 115,857 shares of Aktis Oncology worth $2.26M as of Q3 2026.
  • Citadel Advisors bought 90,320 Aktis Oncology shares in Q3 2026, an estimated $2.2M.
  • Aktis Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #6450 holding.
  • Citadel Advisors first reported a position in Aktis Oncology in Q1 2026 and has held it in 3 quarters since.
  • 124 funds tracked by Wall St. Rank held Aktis Oncology as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.